Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medtronic Studies Cryoballoon As First-Line Atrial Fibrillation Option

This article was originally published in The Gray Sheet

Executive Summary

The firm will recruit over 200 patients across 12 European sites to evaluate if its Arctic Front Advance ablation therapy can benefit as a first-line treatment for atrial fibrillation rather than drugs.

You may also be interested in...

New Products In Brief

Debuts include Medtronic’s next-generation Arctic Front Advance for paroxysmal atrial fibrillation, Covidien’s iDrive Ultra surgical stapler and AngioDynamics’ BioFlo peripherally inserted central catheters.

AF Ablation: Surgery And Catheter Techniques Both Shine At AHA

Atrial fibrillation treatments involving standalone surgical ablation and catheter ablation were discussed in data presentations at the American Heart Association annual meeting last week.

Health And Wellness Trademark Review 14 January, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts